4:23 pm IDERA PHARMACEUTICALS, INC. IDRA KARR ROBERT W
(Director) 5,750 $1.759 $10,114 6,299
5:21 pm IDERA PHARMACEUTICALS, INC. IDRA REARDON WILLIAM S
(Director) 13,561 $1.817 $24,643 18,794
5:21 pm IDERA PHARMACEUTICALS, INC. IDRA GERAGHTY JAMES A
(Director) 60,000 $1.9 $114,000 360,000
4:29 pm IDERA PHARMACEUTICALS, INC. IDRA GERAGHTY JAMES A
(Director) 300,000 $1.75 $525,000 300,000
Not only the CEO, but a couple of directors also buying at or above $1.75. Plus Baker Bros and First Eagle added last quarter. I've got IDRA on my watch list, something's brewing.
I doubt we fall below $2, given the recent shelf filing, but I'm concerned we could easily see a further pullback if the overall market goes south. Anyone taking some profits here?
Baker Bros and FIrst Eagle added over 6 Million shares last quarter of IDRA. I wonder why they are so interested in this Cambridge Biotech with a mere $70 Million dollar market cap ? You think they might want to acquire more? ;-)
That's a great charting site, been watching IDRA there. Agree with the bullish reversal. Interesting how someone suggested earlier this week the recent pullback was in anticipation of a public offering and that we'd move up after it was released. I'll be buying today for sure.
Unfortunately we have only weak support at levels above $2. While a retrace to $1.57 is unlikely, it would put us at the midpoint of the 50 and 200DMA average, a possibility should we see a market sell off due to an extended government shutdown or worse, a threat of government default. Keep your Stops tights on CUR.
resist. 3.11 1
resist. 2.84 2
resist. 2.71 2
supp 2.50 2
supp 2.21 2
supp 2.07 2
supp 1.99 2
supp 1.80 3
supp 1.74 2
supp 1.57 21
supp 1.45 6
supp 1.37 6
supp 1.29 2
supp 1.17 6
Should get interesting.
I can't think of one Cambridge MA biotech with market cap under $100m with such a strong advisory board. I agree, the price level here is ridiculously cheap.
When it hits $14. That's my target. The story of Idera is yet to be told. 1k shares at $14 (from 1.55) will net you a nice profit. Best of luck.
I couldn't believe it when I saw the filings on Friday.
I wonder what they know? All 13G filings posted in the past week or so.
Idera seems pretty close with a cure Psoriasis with IMO-8400, probably $4 billion annually near term, increasing to an $8.2 billion dollar market by 2020.
I guess that explains all the ownership. Here's some hard data:
Monthly Rotation Number
of Shares Value of
Change (MM) % of Shrs.
Buyers 10/11/13 26,312,285 $29.30 55.4%
Sellers 10/11/13 1,517,479 $1.12 1.9%
6.8M $11,787,096 +19% 11.5% --
4.5M $7,873,500 +13% 7.7% Moderate
Baker Bros. ...
4.5M $2,947,500 +13% 7.6% Low
Longwood Capital ...
3.8M $2,656,790 +11% 6.4% --
3.3M $5,689,800 +9% 5.6% High
Vega Investment ...
3.1M $2,062,540 +9% 5.4% Low
2.6M $1,822,600 +7% 4.4% --
First Eagle ...
2.0M $1,310,000 +6% 3.4% Low
Dimensional Fund ...
1.0M $656,986 +3% 1.7% Low
845.2K $1,470,580 +2% 1.4%
Um, perhaps you should check their website. It's most certainly posted. I'd provide a link, but Yahoo tends to trim those messages.
Also noticed an SEC filing with Pillar Investments now reporting a 19.9% stake in IDRA. Broadfin also reported holding 7% of the company last week. I wonder why we have such interest all of a sudden?
Thinking of opening a position. MGuard makes a lot of sense from a clinical prospective, how much of a game changer could this be? Has the company projected market share they could take from traditional stent technology? Also where does this stent stand with regards to approval for general use? Thanks.